Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management [Corrigendum]
Al-Janabi A, Yiu ZZN. Psoriasis (Auckl). 2022;12:1–14. The authors have advised that there is an error in Table 1 on page 2. The text “IL-7A” in the Target column for the Ixekizumab row should read “IL-17A”. The authors apologize for this error. Read...
Saved in:
Main Authors: | Al-Janabi A (Author), Yiu ZZN (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2022-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management
by: Al-Janabi A, et al.
Published: (2022) -
Long-term safety of biologics in the treatment of psoriasis
by: Panchal MR, et al.
Published: (2013) -
Assessment and monitoring of biologic drug adverse events in patients with psoriasis
by: Hanley T, et al.
Published: (2016) -
Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab
by: Hanley TL, et al.
Published: (2017) -
Update on biologic safety for patients with psoriasis during pregnancy
by: Martina L. Porter, et al.
Published: (2017)